- |||||||||| Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Clinical: Finally, hope on way: new outpatient tx for high risk kids ≥12y to decrease hosp risk include paxlovid (oral), convalescent plasma, sotrovimab + evusheld for pre-exposure prophylaxis in immunocompromised. All in short supply, but when more available, will help ⬇️ hosp #. 22/ (Twitter) - Dec 31, 2021
|